Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:55 - Any
Updated:4/21/2016
Start Date:August 2014
End Date:March 2016
Contact:Alison Schneider, M.D.
Email:schneia2@ccf.org
Phone:954-659-5646

Use our guide to learn which trials are right for you!

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients: A Randomized Clinical Trial

The purpose of this study is to test if metronidazole prophylaxis is effective in decreasing
the incidence of hospital induced Clostridium Difficile diarrhea among patients at high risk
for this infection.

Clostridium Difficile infection or C. Diff (CDI) is an infection that causes severe
diarrhea. Risk factors for this infection include hospitalization, the use of antibiotics,
along with medications that decrease the acid in the stomach. This infection leads to a
disease which is difficult to treat and can cause serious complications including death in
rare cases. This infection also increases medical costs by prolonging hospital stays.

Metronidazole (known by the brand name Flagyl) is an antibiotic that has been available for
decades and has been used to treat this disease. Flagyl is approved by the Food and Drug
Administration for the treatment of C. diff infection. Recent research by the investigators
group has shown that hospitalized patients who took Flagyl had a decreased chance of getting
C. Diff infection. However, high quality studies are needed to better evaluate whether the
investigators can prevent C. Diff infection in high risk patients with the use of Flagyl.

The purpose of this study is to assess if metronidazole prophylaxis is effective in
decreasing the incidence of hospital induced Clostridium Difficile diarrhea among inpatients
at high risk for this infection.

High risk patient population are as defined below: taking a broad spectrum antibiotics
(piperacillin/tazobactam-Zosyn; Ciprofloxacin).

Inclusion Criteria:

- Inpatients >55

- Proton Pump inhibitor / Histamine-2 Blocker

- On broad spectrum antibiotics (Zosyn and/or Ciprofloxacin). These two antibiotics are
selected based on current hospital formulary/use

- Anticipated hospital stay >48 hours

- Mental capacity (able to give informed written consent).

Exclusion Criteria:

- Admission for CDI

- Existing diarrhea at admission

- Passed prophylactic window (>48 hours on broad spectrum antibiotics)

- Unable to take PO at the time of evaluation for study entry

- No more than 14 days of broad spectrum antibiotics anticipated

- Medications with serious interactions/contraindications to that would be taken
together with metronidazole (ex. Warfarin, disulfiram, phenytoin, calcineurin
inhibitors)

- Inflammatory Bowel Disease

- Admission for colonic bowel surgery or h/o total/Subtotal colectomy)

- Hospice

- Mortality expected <7days

- Previous CDI in the past 6 months

- Intensive care admission due to the difficulty of monitoring them

- Allergy to Metronidazole or other Antibiotics in protocol

- Patients with neuropathy

- History of heavy ethyl alcohol intake(greater than 3 drinks daily) or intake in past
24 hours,Solid organ transplant.
We found this trial at
1
site
2950 Cleveland Clinic Blvd.
Weston, Florida 33331
866.293.7866
Principal Investigator: Alison Schneider, M.D.
Phone: 954-659-5646
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
?
mi
from
Weston, FL
Click here to add this to my saved trials